Macquarie Group LTD Macrogenics Inc Transaction History

Macquarie Group LTD

$79.1 Billion
Q2 2025

A detailed history of Macquarie Group LTD transactions in Macrogenics Inc stock. As of the latest transaction made, Macquarie Group LTD holds 420,000 shares of MGNX stock, worth $714,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

420,000

Previous 420,000 -0.0%

Holding current value

$714,000

Previous $533,000 4.69%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 21, 2023	SELL	$3.34 - $6.98 $1,636 - $3,420	-490 Reduced 0.12%	420,000 $2.82 Million
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $2,353 - $4,082	-782 Reduced 0.19%	420,490 $1.46 Million
Q4 2021 Feb 11, 2022	SELL	$15.91 - $21.88 $16,180 - $22,251	-1,017 Reduced 0.24%	421,272 $6.76 Million
Q2 2021 Aug 13, 2021	BUY	$20.49 - $35.63 $18,461 - $32,102	901 Added 0.21%	422,289 $11.3 Million
Q1 2021 May 14, 2021	SELL	$18.99 - $33.2 $8,070 - $14,110	-425 Reduced 0.1%	421,388 $13.4 Million
Q2 2020 Aug 11, 2020	BUY	$5.2 - $29.12 $763,427 - $4.28 Million	146,813 Added 53.39%	421,813 $11.8 Million
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $217,650 - $295,650	15,000 Added 5.77%	275,000 $4.67 Million
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $2 Million - $4.61 Million	180,000 Added 225.0%	260,000 $4.68 Million
Q1 2018 May 11, 2018	BUY	$18.89 - $32.46 $566,700 - $973,800	30,000 Added 60.0%	80,000 $2.01 Million
Q3 2017 Nov 08, 2017	BUY	$15.52 - $18.94 $776,000 - $947,000	50,000	50,000 $924,000

Others Institutions Holding MGNX

# of Institutions

119

Shares Held

52.3M

Call Options Held

55.3K

Put Options Held

35.9K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $104M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Macrogenics Inc Transaction History